

## PERSONAL INFORMATION

<u>Date of Birth</u>	July 11, 1962
<u>Citizenship</u>	Lebanese
<u>Permanent Residency</u>	Canada
<u>Marital Status</u>	Married 2 daughters
<u>Email</u>	<a href="mailto:drfadi@drfadi.org">drfadi@drfadi.org</a> <a href="mailto:drfadi.clinic@gmail.com">drfadi.clinic@gmail.com</a>
<u>Website</u>	<a href="http://www.drfadiFarhat.com">www.drfadiFarhat.com</a>
<u>Clinics Adress</u>	Mount Lebanon Hospital, Beirut Hammoud Hospital UMC, Saida Clemenceau Medical Center, Beirut
<u>Fax</u>	(+961) 07 754 155
<u>Clinics Phone</u>	(+961) 01 753 155 (+961) 07 753 155
<u>Personal Phone</u>	(+1) 4385 22 4385 (+961) 03 753 155
<u>Languages</u>	Arabic, English, French, & Russian (All spoken & written)



## ACADEMIC &amp; SCIENTIFIC APPOINTMENTS

- 2000-Present Head of Hematology-Oncology Division; Hammoud Hospital University Medical Center, Saida
- 2006-2011 Head of Hematology-Oncology Division, Nabih Berri Governmental Hospital, Nabatieh
- 2013-2016 Head of Clinical Research Unit, Nabih Berri University Hospital, Nabatieh
  
- 2013-Present President of the “Cancer Research Group - Collaborative Group” [CRG-CG]
- 2014-2016 President of the “Lebanese Society of Medical Oncology” [LSMO]
- 2015-Present Co-founder and Treasurer of the “Africa Middle East Cancer Intergroup” [AMCI]
- 2015-Present Chairman of the “Rare Gastro-Intestinal Working Group” MENA region.
  
- 1998-2005 Lecturer - Course of Hematology Oncology; Public Health Faculty; Lebanese University, Saida
- 2004-Present Lecturer - Course of Medical Oncology. Faculty of Medicine; Saint Joseph University, Beirut
- 2004-Present Lecturer- Course of Hematology. Faculty of Medicine; Saint-Joseph University, Beirut
- 2012-Present Lecturer- Public Health Course. Faculty of Medicine; Saint-Joseph University, Beirut
- 2013-2015 Lecturer- Course of Oncology. Faculty of Medicine; Lebanese University, Beirut.
  
- 2006-Present Attached Physician- Hematology-Oncology Division, Hotel-Dieu-De France, Beirut
- 2008-Present Consultant- Hematology-Oncology Division, Mount-Lebanon Hospital, Beirut
- 2012-Present Consultant- Hematology-Oncology Division, Clemenceau Medical Center, Beirut

UNIVERSITY DIPLOMAS

- 2012 Health and Hospital Management- MBA  
Ecole supérieure des Affaires, Université Diderot, Paris, France
- 1995 General Hematology  
University of Paris VI Pierre et Marie Curie, France
- 1995 Breast Diseases  
University of Paris VII Lariboisière Saint – Louis, France
- 1994 Medical Oncology  
University of Paris V René Descartes, France
- 1992 Oncological Pharmacology  
University of Paris VII Lariboisière Saint-Louis, France
- 1990 Clinical Cancerology  
University of Paris VI Pierre et Marie Curie, France
- 1988 Medical Doctor  
University of Zaparojie, URSS

CERTIFICATION

- 2002      **Board of Oncology**  
European Society of Medical Oncology Certification (ESMO)
- 2002      **Course of "Clinical Trials in Oncology"**  
Vienna School of Clinical Research  
Vienna, Austria
- 2005      **Business Presentation Skills**  
Management Center Europe course  
Brussels, Belgium
- 2006      **Seminar «Initiation a la pédagogie et l'enseignement médical»**  
Saint-Joseph University  
Beirut, Lebanon
- 2006      **Introduction Situational Leadership II**  
The Ken Blanchard Companies  
Beirut, Lebanon
- 2008      **Health Economics Of Pharmaceuticals And Other Medical Intervention**  
European School of Health Economics  
Nice, France

**SPEAKER INVITATION - INTERNATIONAL CONGRESS**2003

1. Triplet Paclitaxel, Paraplatin, and Gemcitabine in Bladder Cancer and Unknown Primary, Investigators Workshop, Bangkok, Thailand

2006

2. FOLFOX-6 combination in the first-line treatment of locally advanced and/or metastatic pancreatic cancer (APC) International Congress on Anti-Cancer Treatment, Paris, France.
3. Neoadjuvant Chemotherapy Of Breast Cancer  
16<sup>th</sup> Annual Congress of Pan-Arab Association of Surgeons, Amman, Jordan

2007

4. Avastin in metastatic breast cancer: what do we know so far?  
3<sup>rd</sup> International Medical Oncology Conference, Salalah, Oman
5. Role of Trastuzumab (Herceptin) in the Treatment of Early Breast Cancer  
3<sup>rd</sup> International Medical Oncology Conference, Salalah, Oman

2009

1. An update on Small Cell Cancer Treatment  
1<sup>st</sup> Syrian 7 Pulmonology Cancer Congress, Damascus, Syria.

2012

2. Case Report on Neuro-endocrine tumor.  
First Middle East Forum on Neuroendocrine Tumors, Beirut, Lebanon,
3. Presentation of case on metastatic Prostatic Cancer,  
European Arabic School of Oncology – EASO, Beirut, Lebanon.
4. How do I treat Locally advanced NSCLC?  
Near East Medical Association – NEMA 1, Istanbul, Turkey

2013

5. Treatment of GIST: update,  
1<sup>st</sup> conference of Oncolog, Ryad, Kingdom of Saudi Arabia

2014

6. Update on GIST tumors.  
Emirates Oncology Congress, Abou Dhabi, United Arabes Emirates.

2015

7. Role of angiogenesis in Gastro-Intestinal Stromal Tumors.  
Angiogenesis Forum, Amman, Jordan.
8. Update on Gastro-international Stromal Tumors.  
First Iranian Gastro-intestinal National Conference. Teheran, Iran.

2016

14. First line metastatic Renal Cell Carcinoma management, Therapy management and short review about second line.  
Teheran, Iran
15. a) Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC) [67275].  
b) 170759:  
c) Treatment Holidays Are the Standard of care  
The First Rizgary Oncology Center Best of ASCO Conference in Kurdistan, Erbil, Irak
16. « Navigating guidelines in the managment of mCRC: closer look in the new ESMO guidelines. 8th Mucscat International Oncology conference. Muscat, Oman

2017

17. "Angiogenesis in GIST".  
Angiogenesis and Immunotherapy Course, Beirut, Lebanon **Organizers?**

2018 & 2019

Update later

## SPEAKER INVITATION- NATIONAL CONGRESS

1998

1. Cancer in Lebanon: 10 ans d'expérience a l'hôpital Hammoud de Saida. First annual conference of the Lebanese Society of Medical Oncology- LSMO1; Tyr, September

2000

2. Pancreatic papillary cystic tumors. 4th Lebanese Spring Surgical congress, Saida, Mars
3. Study of 33 cases of papillary thyroid carcinoma at Hammoud Hospital in Saida. The third annual cancer congress of the Lebanese Society of Medical Oncology –LSMO 3, Beirut. November
4. Polysite management, The Hammoud Hospital experience. The fourth annual cancer congress of the Lebanese Society of Medical Oncology -LSMO4, Beirut, September

2002

5. Weekly Docetaxel and Gemcitabine in metastatic breast cancer. The fourth annual cancer congress of the Lebanese Society of Medical Oncology -LSMO4, Beirut, September

2005

6. Docetaxel and irinotecan for the treatment of advanced non-small cell lung cancer: A phase II study. Lebanese Society of Medical Oncology 5<sup>th</sup> Forum, LSMO 5 National Forum, Beirut, Lebanon.
7. Irinotecan and etoposide as first line chemotherapy in extensive small-cell lung cancer; preliminary results of a phase II study. Lebanese Society of Medical Oncology 5<sup>th</sup> Forum, LSMO 5 National Forum, Beirut, Lebanon.
8. Aromatase Inhibitors in an adjuvant setting. The Advanced Course Of Mastology, MC56, 10th Spring Lebanese Congress of Surgery, Beirut, July

2006

9. Phase III Trial of Gemcitabine short infusion vs. Gemcitabine fixed dose infusion vs. GEMOX in the treatment of metastatic and locally advanced pancreatic cancer. Best of ASCO 2006 in Lebanon, November

2007

10. Current Advances in Targeted Therapy in Solid Tumors. Lebanese Order of Physicians
11. Introduction to the use of targeted therapy in cancer. Congress « Deuxième journées medico-chirurgicales de langue Française ». Beirut.
12. Smoking, the magnitude of the problem. Middle East Medical Assembly – MEMA,

2008

13. Nursing Considerations With The Use Of Targeted Therapy. 5eme Forum National de la Société Libanaise D'oncologie Médicale, Beyrouth, Liban

2009

14. Non-Small Cell Lung Cancer and Estrogen Plus Progestin Use in Postmenopausal Women in the Women's Health Initiative Randomized Clinical Trial. Best of ASCO Lebanon,

2012

15. Cancer Research Group (CRG): Achievements and clinical trials. National Conference on Ongoing studies in Lebanon, Beirut, Lebanon

2016

16. AMCI and Cancer Clinical Trials in Africa and Middle East. 4<sup>th</sup> Annual Beirut Breast Cancer Conference (Beirut BCC4): Advances in Breast Cancer Management and Updates. February 11-13, 2016 , Beirut, Lebanon
17. Immunotherapy for Lung. October 14-15, 2016. Conference CMC forum
18. Pharmacist

2017

19. Middle East Solid Tumors Meeting: Efficacy and Safety in Strategic Decision-Making.

2018 & 2019

Update later



## PUBLISHED PEER REVIEWED ARTICLES [1]

Phase	AUTHORS	TITLE	YEAR	JOURNAL
Phase II	G. Y. Chahine, F. L. Nasr, J. G. Kattan, F. S. Farhat, M.-E. El Seoudi, M. Bachour, W. T. Moukadem, F. C. Younes...	Phase II trial of weekly docetaxel and carboplatin as first line chemotherapy in advanced or metastatic non-small cell lung cancer	2005	JCO 23(16_suppl):7330-7330
Case report	F Farhat, J Kattan, S Culine, ..... JP Droz.	Liposarcome du cordon spermatique: à propos d'un cas avec revue de la literature.	1994	Bull Cancer, 81, pp. 223-225, 1994.
Case report	F Farhat, J Kattan, S Culine, M Bekradda, JP Droz.	Efficacité de l'association 5-fluorouracile, adriamycine et cisplatine (FAP) dans le traitement des cylindromes métastatiques. A propos d'un cas avec revue de la literature.	1994	Bull Cancer, 81, pp. 47-50, 1994.
Case Report	L Mounedji-Boudiaf, S Culine, ...Farhat, M Bekradda, JP Droz	Lymphome B de grande malignité primitif de la prostate. A propos d'un cas avec revue de la littérature	1994	Bull Cancer, 81, pp. 334-337, 1994
Review	F Farhat, P Ruffié.	Les traitements antiémétiques. CVA ASCO 1994	1994	Cancérologie, pp:18-20, 1994.
Review	L Abs, S Culine, M Bekradda, F Farhat, JP Droz.	Intérêt d'une mono-antibiothérapie par pipéracilline associée au sulbactam et suivie éventuellement par la vancomycine dans les neutropénies fébriles des tumeurs solides	1994	Bull Cancer, 81, pp. 871-876, 1994.
Case Report	F Farhat, S Culine, MJ Terrier-Lacombe, JP Droz.	Adénocarcinome du rete testis. A propos d'un cas avec revue de la littérature	1995	Bull Cancer, 82, pp. 167-172.
Case series	F Farhat, S Culine..... JP Droz	Tumeurs desmoplastiques à petites cellules rondes de l'adulte: une nouvelle entité »...	1995	Bull Cancer, 82, pp. 665-673. 1995
Case Series	S Culine, C Lhomme, F Farhat, JP Droz.	Salvage chemotherapy in non-dysgerminomatous germ cell tumors of the ovary	1995	Eur J Cancer, 31A, 11, pp. 1290-1291.
Case series	F Farhat, S Culine, ..... JP Droz	Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumors: the Institut Gustave Roussy experience	1996	Cancer, 77, pp. 1193-1197.
Case Series	S Culine, C Théodore, F Farhat, ..... JP Droz.	Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors	1996	J Surg Oncology, 61, pp. 195-198.
Case series	F Farhat, S Culine, C Lhomme, P ....., JP Droz.	Desmoplastic small round cell tumors: result of a four-drug chemotherapy regimen in five adult patients»	1997	Cancer, 77, pp. 1363-1366. 1996.
Case series	K Fizazi, F Farhat, C Théodore, O Rixe, E Comoy, T Le Chevallier	Ca 125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round cell tumors»	1997	Br J Cancer, 75, pp. 76-78. 1997.
Case Series	S Culine, C Théodore, M Bekradda, F Farhat, ..... JP Droz	Experience with bleomycine, etoposide, cisplatine (BEP) and alternating cisplatine, cyclophosphamide, bleomycine (Vbiv) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors	1997	Am J Clin Oncol, 20, pp. 184-188.

Case Series	S Culine, I Philippot, F Farhat, ..... JP Droz.	Evaluation of long-term results of a modified VAB-6 chemotherapy regimen in a cohort of good-risk metastatic nonseminomatous germ-cell tumors».	1997	Bull Cancer, 84, pp. 368-672.
Phase IV	Mahfouz RA, Hoteit R, Salem Z, Bazarbachi A, Mugharbel A, Farhat F, Ziyadeh A, Ibrahim A, Taher A	JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: experience of a major referral center in Lebanon.	2001	Genet Test Mol Biomarkers. 2011 Apr;15(4):263-5
Phase II	Fadi Nasr, Georges Chahine, Joseph Kattan, Fadi Farhat et al.	Gemcitabine plus Carboplatine Combination Therapy as second Line Treatment in patients with Relapsed Breast Cancer	2004	Clinical Breast Cancer, 5 (2): 117 – 22. 2004.
Phase II	M Ghosn, Joseph Kattan, Fadi Farhat, Fariha Younes, Jamal Gasmî.	Phase II trial of Capecitabine and Vinorelbine as first line chemotherapy for metastatic breast cancer patients.	2006	Anticancer Research, 2006, vol 26, 3. 2451-2456.
Phase II	Marwan Ghosn Joseph Kattan, Fadi Farhat, Georges Chahine	Sequential Vinorelbine (N) - Capecitabine (C) followed by Docetaxel in Advanced Breast cancer (ABC): Long-term results of pilot Phase II trial	2007	Cancer Chemotherapy and Pharmacology. 2007. Aug 24.
Phase II	Marwan Ghosn, Fadi Farhat ..... Georges Chahine.	FOLFOX-6 Combination As The First-Line Treatment Of Locally Advanced And/Or Metastatic Pancreatic Cancer	2007	Am J of Clin Oncol. 2007. Feb; 30(1): 15-20.
Review	Fadi Farhat	A General Review Of The Role Of Irinotecan (CPT11) In The Treatment Of Gastric Cancer	2007	Medical Oncology. 2007: 24(2):137-46
Case Report	Farhat Fadi, Fakhrudine Najla.	A Case of Synchronous Relapse of Breast Cancer and Uterine Müllerian Adenosarcoma Post Tamoxifen in a Premenopausal Woman	2008	European Journal of Gynaecological Oncology. 2008; 29(1):95-7.
Case Report	Rami Mahfouz; .....Fadi Farhat	Kodamaea (Pichia) ohmeri fungaemia complicating acute myeloid leukaemia in a patient with haemochromatosis	2008	Pathology, 2008. Jan;40(1):99-101.
Case series	Rachid Haidar, S Sagghieh, ....., Fadi Farhat, ..... Miguel Abboud	Limb salvage surgery for children and adolescents with malignant bone tumors in a developing country	2008	Pediatric Blood and Cancer. 2008. Aug 4.
Phase II	Joseph Kattan; Fadi Farhat; Nadine Yazbeck; Marwan Ghosn	Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)	2008	Investigational New Drugs. Feb;26(1):75-9.
Phase II	M. Ghosn, C. Hanna, F. Farhat, ..... Kattan.	Low Dose Docetaxel, Carboplatin and Capecitabine in the Treatment of Recurrent and/or Metastatic Head and Neck Cancer (HNC): Results of a Pilot Phase II Study	2008	Pan Arab Journal of Oncology. Sept. 2008; 1(3): 10-13
Phase II	Yasser Abou-Mourad, Zaher Otrack, ..... Fadi Farhat, ..... Ali Shamseddine.	Docetaxel and irinotecan as first – line chemotherapy in patients with advanced non small cell lung cancer: a pilot study.	2008	Journal Medical Libanais. 56(1):16-21.
Case Report	Fadi S Farhat, Fady Geara..... ..Walid Daya	Tongue carcinoma in an adult Down's syndrome patient: a case report	2009	World J Surg Oncol. 2009; 7: 26.
Phase II	Farhat FS, Kattan J, Chahine GY et al.	Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer	2009	Med Oncol. 2009 Jul 31
Phase IV	Hanane Dahoui, Hayek Munya, .....Farhat Fadi, Bitar Fadi, Abboud Miguel.	Pulmonary Hypertension in Children and Young Adults with Sickle Cell Disease: Evidence for Familial Clustering	2009	Pediatric Blood & Cancer, 2009

Phase II	M. Ghosn, P. Aftimos, FS. Farhat et al.	A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer.	2010	Med Oncol. Dec 7. 2010.
Review	Fadi S. Farhat, Joseph Kattan, Marwan G. Ghosn.	Role Of Capecitabine And Irinotecan Combination Therapy In Advanced Or Metastatic Gastric Cancer	2010	Expert Review, April 2010
Case Series	Marwan Ghosn, Carla Hajj, Joseph Kattan, Fadi Farhat et al...	Triple-Negative Breast Cancer in Lebanon: A Case Series.	2011	The Oncologist 2011; 16:1552–1556
Phase II	Fadi Farhat; Sally Temraz; Joseph Kattan et al.	A Phase II Study of Lipoplatin (Liposomal Cisplatin) - Vinorelbine Combination in HER-2/neu Negative Metastatic Breast Cancer	2011	Clinical Breast Cancer. 2011
Review	Ali Shamseddin, Fadi Farhat	Platinum-based Compounds for the Treatment of Metastatic Breast Cancer	2011	Chemotherapy. 2011
Phase II	Ghosn M..... Farhat F	Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer	2012	Med Oncol. Dec;29(4):2831-7
Phase II	Kattan JG, Boutros CY, Farhat FS, ..... Ghosn MG.	Sequential therapy with gemcitabine and Carboplatin followed by Paclitaxel as first line treatment for advanced urothelial cancer.	2012	J Cancer; 3: 362-8.
Phase IV	Otrock ZK, Mahfouz RA, Fahed Z, Farhat FS, Ziade A, Nasr F, Kassem N, Abboud MR.	Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.	2012	Int J Hematol. 2012 Oct;96(4):521-4.
Review	Fadi S. Farhat, Arafat Tfayli..... Ali Shamseddine	Expression and prognostic impact of VEGF and bFGF in non-small cell lung cancer.	2012	Crit Rev Oncol Hematol. Nov;84(2):149-60.
Phase II	Shamseddine A, Farhat FS, Elias E, Khauli RB, Saleh A, Bulbul MA.	High -dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study.	2013	Urol Int.; 90(1):56-61.
Phase IV	Zaher K. Otrock, Jad Saab, Georges Aftimos, Fady Nasr, Fadi S. Farhat..Ali Bazarbachi	A Collaborative Nationwide Lymphoma Study in Lebanon: Incidence of Various Subtypes and Analysis of Associations with Viruses.	2013	Pathology & Oncology Research; May 2013.
Review	Fadi S Farhat, Wissam Houhou	Targeted Therapies In Non-Small Cell Lung Carcinoma: What Have We Achieved So Far?"	2013	Therapeutic Advances in Medical Oncology; vol 5, 4 July,
Case Series	Najla Fakhruddin, Rami Mahfouz, Fadi Farhat, ..... Ghazi Zaatari	Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: A retrospective study of the Lebanese population.	2014	Oncology Reports
Review	Fadi S Farhat, Joseph G Kattan	Nursing Considerations with The Use Of Targeted Therapy.	2014	Journal Medical Libanais. S26, Vo I 56.
Review	Rim S. Ishak, Simon Abi Aad, Angela Kyeidi, Fadi S. Farhat.	Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors..	2014	Critical Reviews in Oncology /Hematology 90, 2, 152–164, May 2014
Cohort	Tarek Assi & Elie El Rassy & Samer Tabchi & Toni Ibrahim & Tania Moussa & Ralph Chebib & Fadi El Karak & Fadi Farhat & Georges Chahine & Fadi Nasr & Marwan Ghosn & Joseph Kattan	Treatment of cancer patients in their last month of life aimless chemotherapy	2015	Support Care Cancer DOI 10.1007/s00520-015-2959-3

Phase II	Fadi S. Farhat, Marwan G. Ghosn, Joseph G. Kattan	Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer.	2015	Cancer Chemotherapy and Pharmacology. May
Review	F. Chehade, M. Ghosn, .... F. Farhat, J. Daher, M. Jreige, M. Haidar.	Approches de la médecine nucléaire au Liban dans les tumeurs neuroendocrines. Trends of nuclear medicine in Lebanon in neuroendocrine tumors	2015	Médecine Nucléaire – Imagerie fonctionnelle et métabolique. V 39 - March.
Review	Simon Abi Aad, Matthew Pierce, .....Fadi S. Farhat, Alexandre Benjo, Elie Mouhayar.	Hypertension induced by chemotherapeutic and immunosuppressive agents: A new challenge. Critical.	2015	Reviews in Oncology/Hematology 93;28–35. 2015.
Case Series	Elias Chelala, Hampig Khourye, ....., Fadi Farhat, Joseph Kattan.	Central Macular Thickness Monitoring After a Taxane-based Therapy in Visually Asymptomatic Patients.	2016	Chemotherapy 2016.
Cohort	Tarek Assi & Elie El Rassy & Aline Khazzaka & Tania Moussa & Tony Ibrahim & Clarisse Kattan & Fadi El Karak & Fadi Farhat & Marwan Ghosn & Joseph Kattan	Characteristics of Gastric Cancer in Lebanon a Descriptive Study from a Single Institutional Experience	2016	J Gastrointest Canc DOI 10.1007/s12029-016-9903-8
Phase II	Fadi Farhat, Joseph G. Kattan, Marwan Ghosn	Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positiv	2016	Cancer Chemother Pharmacol. 2016 May;77(5):1069-77
Phase II	Joseph Kattan & Marwan Bachour & Fadi Farhat & Elie El Rassy & Tarek Assi & Marwan Ghosn	Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer	2016	Invest New Drugs. DOI 10.1007/s10637-016-0357-4
Phase IV	Tarek Assi, Joseph Kattan, Elie El Rassy, Samer Tabchi, Ralph Chebib, Tania Moussa, Colette Hanna, Fadi El Karak, Fadi Farhat, Marwan Ghosn	Efficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country Real-life single institutional experience	2016	Journal of Cancer Research and Therapeutics · June 2016
Phase IV	Zaher K. Otrrock, Nabil Chamseddine... Fadi S. Farhat...Hussein Z. Farhat	A Nationwide Non-Interventional Epidemiological Data Registry on Myelo-dysplastic Syndromes in Lebanon”.	2016	Hematology/Oncology and Stem Cell Therapy. 2016.
Review	ElieEl Rassy.....Fadi Farhat: Joseph Kattan <sup>a</sup> .	Pancreatic small cell cancer.	2016	Clinics and Research in Hepatology and Gastroenterology, 40, 3
Review	F. Farhat, A. Othman, G. el Baba, J. Kattan.	Revealing a cancer diagnosis to patients: attitudes of patients, families, friends, nurses, and physicians in Lebanon—results of a cross-sectional study	2016	Curr Oncol. 2015 Aug; 22(4).
Review	Fadi Fahat, Fadi Elkarak, Ahmad Othman, Joseph Kattan.	Review And Results Of A Survey About Biosimilars Prescription And Challenges In The Middle East And North Africa Region	2016	Springer plus, First Online: 30 December 2016
Review	Tarek Assi & Elie El Rassy & Tony Ibrahim & Tania Moussa & Aline Tohme & Fadi El Karak & Fadi Farhat & Salma Faddoul & Marwan Ghosn & Joseph Kattan	The role of palliative care in the last month of life in elderly cancer patients	2016	Support Care Cancer DOI 10.1007/s00520-016-3444-3
Case report	Najla Fakhruddin..... Fadi Farhat	Hepatoid Adenocarcinoma of the Stomach: A Challenging Diagnostic and Therapeutic Disease through a Case Report and Review of the Literature.	2017	Frontiers in Medicine. ID: 299661.
Case report	T. Assi, E. El Rassy, G. Abi-Tayeh, C. Sader-Ghorra, G. Abadjian, R. Eid, T. Moussa, F. Farhat, J. Kattan	Chemotherapy-induced differentiation to cure botryoid rhabdomyosarcoma A case report and review of the literature	2017	Eur. J. Gynaecol. Oncol. - ISSN: 0392-2936 XXXVIII, n. 2, 2017

Case Series	Arafat Tfayli, Hind Rafei, Alain Mina, ..... Fadi Farhat, ..... Ghazi Zaatari.	Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis.	2017	Asian Pac J Cancer Prev, 18 (1), 107-114
Case series	Fadi El Karak...Fadi Farhat...Mohamad Haidar	PET/CT Scanner and Bone Marrow Biopsy In Detection Of Bone Marrow Involvement In Diffuse Large B-Cell Lymphoma	2017	PONE-D-16-22802R3
Case Series	Najla Fakhruddin, Mark Jabbour, Michael Novy.....Fadi Farhat.....Rami Mahfouz	BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF mutations Between Primary and Corresponding Lymph Node Metastases.	2017	Scientific Reports
Review	El Shamieh S <sup>1</sup> , Saleh F <sup>1</sup> , Fawaz MA <sup>1</sup> , Siest G <sup>1</sup> , Farhat FS <sup>1</sup> , Visvikis-Siest S	Next generation sequencing and immuno-histochemistry profiling identify numerous biomarkers for personalized therapy of endometrioid endometrial carcinoma	2017	Clin Chem Lab Med. 2017 Jun 29.
Review	Fadi Farhat, Simon Abi Aad, Lopez	The Concept of Biosimilars: from Characterization to Evolution - A Narrative Review	2017	The Oncologist
Review	Joseph Kattan, Roland Eid, Hampig Raphael Kourie, Fadi Farhat, Marwan Ghosn, Claude Ghorra, Roland Tomb	Mesotheliomas in Lebanon Witnessing a Change in Epidemiology	2017	Asian Pac J Cancer Prev, 17 (8), 4169-4173
Case Genom	El Shamieh S, Saleh F, Moussa S, Kattan J, Farhat F.	RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple negative breast cancer"	2018	Pharmacogenomics. 2018 Jun 1;19(9):757-760
Case Report	Joya Hadchiti, Francois Kamar, Fadi Farhat and Feras Chehade	<sup>18</sup> F- uoro-2-deoxyglucose positron emission-computed tomography in a rare cutaneous form of Rosai-Dorfman disease: A case report	2018	Molecular & Clinical Oncology 8: 236-241, 2018
Case report	Marwan El Mobadder, Fadi Farhat, Samir Nammour.	Photobiomodulation therapy in the treatment of oral mucositis, dysgeusia and oral dryness as side effects of head and neck radiotherapy in a cancer patient: a case report.	2018	Dent. J. 2018, 6, 64.
Case report	Ralph Chebib, Roland Eid, Fadi Farhat, Joseph Kattan and Claude Ghorra	Aggressive Grade 2 Neuroendocrine Tumor Salvaged by Temozolomide- Based Therapy- A Case Report and Literature Review	2018	Oncol Cancer Case Rep 2018;4:2
Cohort	Elie El Rassy Marwan Ghosn Fadi Farhat Ziad Bakouny Tarek Assi Georges Chahine Fadi Nasr Fady Ghassan Haddad Fadi El Karak Joseph Kattan	Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer A Multicenter Prospective Real-Life Experience	2018	Breast Care 2018;13:121–125
Review	Elie El Rassy, Fadi Farhat & Joseph Kattan	The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis	2018	Immunotherapy (2018) 10(15), 1289–1291
Review	Mervat Mattar on behalf of Collaborators of the NETwork for Drug Quality and Safety (NEDQAS)	On the use of substandard medicines in hematology: An emerging concern in the Middle East and North Africa region	2018	
Review	Ziad Bakouny, Elie El Rassy, Fares Yared, Antoine Abi Lutfallah, Marwan Ghosn, Fadi Farhat & Joseph Kattan	Is there a role for the platelet-to-lymphocyte ratio in chronic lymphocytic leukemia?	2018	Future Science OA
Case Genom	El Shamieh S, Saleh F, Moussa S, Kattan J, Farhat F.	Next generation sequencing reveals a nonsense mutation in RB1 that may promote chemo-resistance to palbociclib in ovarian cancer	2019	Drug Metabolism and Personalized Therapy

Case Report	F Farhat, M Tarabaih, A Kanj, M Aoun, J Kattan, T Assi, A Awada	Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient	2019	Anti-cancer Drugs
Case Report	F Farhat, M Tarabaih, J Kattan, T Assi	Un cas de cancer du sein dans la seule famille libanaise atteinte de la maladie de Fabry	2019	Bulletin de cancer
Case Report	Farida Abi Farraj, Hadi Sabbagh, Tarek Aridi, Najla Fakhruddin and Fadi Sami Farha	Signet Ring Cell Carcinoma of the Colon in Young Adults: A Case Report and Literature Review	2019	Case Reports in Oncological Medicine
Case Report	J Kattan, C Kattan, F Farhat, T Assi.	Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibition in advanced melanoma: A case report.	2019	Anti-cancer Drugs
Case report	Marwan El Mobadder, Fadi Farhat, Samir Nammour.	Photobiomodulation Therapy in the Treatment of Chronic Dysphagia Post Hormonal Therapy in a Breast Cancer Patient	2019	Dent. J. 2019, 7, 53
Case report	Marwan El Mobadder, Fadi Farhat, Samir Nammour.	Photobiomodulation Therapy in the Treatment of Chronic Dysphagia Post Hormonal Therapy in a Breast Cancer Patient	2019	Dent. J. 2019, 7, 53
Case series	Elie Rassy, Fadi El Karak; Josiane Bassil; Mohamed Awali; Colette Hanna; Anthony Saroufim; Fadi Nasr; Fadi Farhat; Joseph Kattan; Marwan Ghosn; Mike Paulden.	Impact and Cost-Effectiveness of Oncotype DX for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer.	2019	Clinical Oncology
Phase IV	Fady El Karak, Fady Gh Haddad', Roland Eid, Maya Al Ghor, Elie El Rassy, Nizar Ahmadih, Theresia Choullamy, Nour A Halim, Arafat Tfayli, Fadi Farhat, Joseph Kattan, Fady Nasr, Marwan Ghosn & Hazem Assi	Lung Cancer and Immunotherapy: A Real-Life Experience from Second Line and Beyond	2019	Future Oncology
Phase IV	Marwan Ghosn, Emad Hamada, Hamdy Abdel Azim, Jamal Zekri, Mubarak Al-Mansour, Mohammed Jaloudi, Fadi Nasr, Hassan Errihani, Adda Boundedjar, Amel Mezlini, Hamouda Boussem, Joseph Kattan, Fadi El Karak, Fadi Farhat	OSSMAR: An Observational Study to describe the use of sunitinib in real-life practice for the treatment of Metastatic Renal Cell Carcinoma	2019	Journal of Global Oncology
Review	Deborah Mukherji · Bassem Youssef · ..... · Fadi Farhat · Muhammad Bulbul · Sally Temraz · Ali Shamseddine · Silke Gillessen · Aurelius Omlin · Raja Khauli	Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations	2019	World Journal of Urology
Case Genom	Salim Moussa, Fatima Saleh, Said El Shamieh, Fadi Farhat	Detection of PIK3R1 (L449S) mutation in a patient with ovarian cancer: a case report	2020	Case Rep Oncol 2020;13:188–192
Cohort	Fadi S. Farhat, Mohamed Tarabey, Feras Chehade,, Tarek Assi, Joseph Kattan	Current status of cancer-related pain and opioid use in South Lebanon: A pilot study	2020	The Gulf Journal of Oncology (GJO). 2020 SEP

Review	Tarek Assi Joseph Kattan Elie Rassy Hussein Nassereddine Fadi Farhat Charles Honore Axel Le Cesne Julien Adam Olivier Mir	Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review on	2020	Critical Reviews in Oncology/ Hematology.153, September 2020, 103029
Review	Assi, Tarek; Rassy, Elie; Farhat, Fadi; Kattan, Clarisse; Kattan, Joseph.	Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review.	2020	Oncol Res Treat ; : 1-8, 2020 May 07.
Review	Fadi Farhat, Abdulaziz Al Farsi, Ahmed Mohieldin, Bassim Jaffar Al Bahrani, Eman Sbaity, Hassan Jaffar, Joseph Kattan, Kakil Rasul, Khairallah Saad, Tarek Assi, Waleed El Morsi and Rafid A Abood	Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries	2020	World Journal of Clinical Cases Manuscript
Review	Tarek Assi, Elie Rassy, Hussein, Nassereddine, Fadi Farhat, Fadi ElKarak, Joseph Kattan, Marwan Ghosn	TRK inhibition in soft tissue sarcomas: A comprehensive review	2020	Seminars in Oncology Volume 47, Issue 1, February 2020, Pages 73-84
Review	Tony Ibrahim, Abir Ahmadi, Elie Rassy, Fadi El Karak, Colette Hanna, Fadi Farhat, Joseph Kattan, Marwan Ghosn	Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer : A feasibility study in daily clinical practice	2020	Bull Cancer. 2020 Apr;107(4):410-416
Review	T. Assi · E. El Rassy· F. Farhat · J. Kattan	Overview on the role of preoperative therapy in the management of kidney cancer	2020	lin Transl Oncol 2020 Jan;22(1): 11-20.

## SUBMITTED FOR REVISION

Review	Ali Shamseddine, George Chahine, <b>Fadi Farhat</b> ..... Mar Peeters	Tailored treatment guidelines for patients with metastatic colorectal cancer in Lebanon		
Case	<b>Fadi Farhat</b> ; Said El Shamieh; Tarek Assi; Fatima Saleh; Mohammad Cham; Ahmad Othman	Poor response to Erlotinib in ovarian cancer patient with EGFR G796S mutation		
Review		Pain evaluation in a tertiary center		
Review	Arafat Tfayli, MD, FRCP; Fadia Elias, MD; Rita Slim; Zeinoun Hallal; Layal Maatouk; Islam Anan; Ahmed Ibrahim, BSc; <b>Fadi Farhat, MD</b>	Cost Effectiveness Analysis in Advanced Non-Squamous Non-Small-Cell Lung Cancer in Lebanon: A Comparison Between First-Line Bevacizumab with Paclitaxel and Carboplatin Versus Pemetrexed with Carboplatin		

## CLINICAL RESEARCH/Principal Investigator – Phase II

FIELD	Title	Protocol	Outcome
Brain	Phase II Trial Of Temodal And BICNU In The Second Line Treatment Of Brain Tumors	CRG CE 025	
Breast	A Phase II randomized study comparing vinorelbine and capecitabine(NavCap) with sequential NavCap followed by weekly docetaxel (NavCap-Taxotere) in the first line treatment of metastatic breast cancer	CRG SE 012	Article
	A phase II Study Of Gemzar and Carboplatine in The Treatment Of Relapsed Metastatic Breast Cancer	CRG SE 003	Article
	A Phase II Study Of The Combination Capecitabine And Vinorelbine As Salvage Chemotherapy In Advanced Or Metastatic Breast Cancer	CRG SE 000	Article
	A Phase II Study Of The Combination Capecitabine And Vinorelbine followed by Taxotere As Salvage Chemotherapy In Advanced Or Metastatic Breast Cancer	CRG SE 001	Article
	A phase II trial Epirubicin / Docetaxel In The Neoadjuvant Treatment Of Breast Cancer	CRG SE 027	Article
	A phase II trial Gemzar and Caelyx in the second line treatment of metastatic Breast cancer	CRG SE 013	None
	Gemzar and Taxol as second line treatment for Metastatic Breast cancer	CRG SE 014	
	Lipoplatine Breast		Article
	Phase II study of the combination Docetaxel Carboplatine and Capecitabine as first line chemotherapy in advanced or metastatic breast cancer	CRG SE 002	Article
	Phase II Trial Of Gemzar And Oxaliplatin In The Second Line Treatment Of Metastatic Breast Cancer	CRG SE 026	None
	Phase II trial of oral vinorelbine in combination with taxotere as first line therapy in women with previously untreated HER2 negative metastatic breast cancer	CRG SE 036	Article
	Phase II trial of oral vinorelbine in combination with trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer	CRG SE 034	Article
CUP	A phase II study of Gemzar and Oxaliplatin for metastatic carcinoma of Unknown Primary	CRG OI 032	None



GI	A multicenter, single arm, phase II of adjuvant imatinib mesylate (Glivec), in patients following the resection of primary gastro-intestinal stromal tumor (GIST)	AB Science	?
GI	FOLFOX-6 In The Treatment Of Advanced Pancreatic Cancer	CRG PA 011	Article
GI	Phase II Study Of Irinotecan/Xeloda In The First Line Treatment Of Metastatic Colon Cancer	CRG CO 009	Article
GI	Phase II study of sequential FOLFOX 6 followed by Gemcitabine in the first line treatment of locally advanced or metastatic Pancreatic cancer	CRG PA 031	Article
GI	Phase II Study Of The Combination Irinotecan And Capecitabine As First Line Chemotherapy In Advanced or Metastatic Gastric Cancer	CRG SE 008	Article
GI	Phase II Study Of The Combination Taxotere, oxaliplatin And Capecitabine As First Line Chemotherapy In Advanced or Metastatic Gastric Cancer	CRG GE 035	None
GI	Phase II Trial Of Sequential Chemotherapy: FLOX Followed By Capelri As Front Line Chemotherapy For Advanced Colorectal Cancer	CRG CO 030	Article
GI	Randomized phase II trial evaluating different schedules of CPT11 combined with efusional or bolus 5FU/FA as a front-line therapy for advanced colorectal cancer.	Rhone-Poulenc Rorer Pharma	Article
GU	High -dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study.	AUBMC	Article
GU	A phase II Study Of Gemzar / Taxol / Carboplatine In The First Line Treatment Urothelial Cancer	CRG VE 006	Article
GU	A phase II study of Taxotere/Estracyt/Zometa in The First Line Treatment Of Metastatic Prostate Cancer	CRG PR 004	Article
GU	A phase II study of weekly Docetaxel, Zoledranate And Selenium For Androgen-Independent Prostatic Cancer	CRG PR 029	
GU	Association of Gemzar to Carboplatine followed by Taxol as first line treatment for metastatic Urothelial cancer	CRG VE 024	Article
GU	Phase II Trial Of Weekly Docetaxel, Zoledonate And Celecoxib For Androgen Independent Prostate Cancer Patient	CRG PR 019	
GYN	Phase II Study Of The Weekly Combination Gemzar/Taxol/ Carboplatine As First Line Chemotherapy in Stage III/IV advanced Or Metastatic Ovarian Cancer	CRG OV 020	None
GYN	Phase II Trial Of Topotecan And Caelyx In The Second Line Treatment Of Metastatic Ovarian Cancer	CRG OV 021	None
H&N	Taxotere, carboplatine & xeloda as first line treatment for Head & Neck cancer	CRG OR 010	Article

Hemato	Irinotecan and Gemzar used as second or more line of treatment for NH lymphoma	CRG LN 022	None
Lung	A phase II Randomized Of Weekly Docetaxel And Carboplatine Followed By Docetaxel Weekly In Advanced Or Metastatic Non Small Metastatic Lung Cancer	CRG PO 028	
Lung	A phase II Study of Irinotecan/Etoposide in The First Line Treatment Of Small Cell Lung Cancer	CRG PO 005	Abstract
Lung	A Phase II Trial Of Weekly Gemcitabine And Vinorelbine As Salvage Treatment Of NS Metastatic Non Small Cell Lung Cancer CLC	CRG PO 018	
Lung	Phase II Study Of Combination Paclitaxel And Hycantin As Second Line Chemotherapy In Advanced Or Metastatic Small Cell Cancer	CRG PO 016	None
Lung	Phase II Trial Of Irinotecan And VP16 Followed By Carboplatine In The First Line Treatment Of Metastatic Small Cell Lung Cancer	CRG PO 015	
Lung	Phase II trial of Taxotere in the treatment of Non-Small Cell Lung Cancer in stage III-IV, Roger Bellon. Medical Department, Montpellier Regional Cancer Center	Roger Bellon Pharma	Article
Lung	Prospective phase II trial of oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first line chemotherapy for locally advanced or metastatic non-small-cell lung cancer patients	CRG PO 033	Article
Lung	Taxotere and Carboplatine as first line treatment for Metastatic Non Small Cell Cancer	CRG PO 017	
Lung	Docetaxel and irinotecan as first – line chemotherapy in patients with advanced Non Small Cell Lung Cancer: a pilot study	AUBMC	Article
STS	Taxotere and Temodal as first or more line of chemohrapy for malignant Melanoma	CRG CE 023	None
Supportive Care	Phase II double blind randomised trial of DAU 6215, for the control of acute emesis in high dose cisplatin treated cancer patients, Boehringer Ingelheim France. Medical Department, Institute Gustave Roussy - Ville Juif	Boehringer Ingelheim	Abstract
Supportive Care	The comparison of Kytril to Zofran in the prevention of nausea and vomiting during chemotherapy	CRG TS 007	None

## CLINICAL RESEARCH/Principal Investigator - Phase III

FIELD	Title	Protocol	Outcome
Breast		MONALEESA-2	
Breast		MONALEESA-7	
Breast	A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121 B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer.	IMCI CP12-0606trRIO-012:	
Breast	A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole	BOLERO-6	
Breast	An open label, randomized phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment.	LUX Breast I	
Breast GI	Neoadjuvant A prospective, multicenter, randomized, double-blind, placebo controlled, 2-parallel group, Phase III study to compare efficacy and safety of Masitinib at 9 mg/kg/day in combination with Gemcitabine, to Placebo in combination with Gemcitabine, in treatment of patients with advanced/metastatic pancreatic cancer	Pancreas ABS	
Hemato Hemato		CATCH CRAD001N2 301	
Hemato	"Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients".	CAMN107E2 401	
Hemato	A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects with Previously-Treated Indolent Non- Hodgkin Lymphoma		
Hemato	A randomized, double-blind, placebo-controlled, multi-center phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy		
Hemato	Extending molecular responses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd)	(ENESTxtnd)	

---

Lung	ASA trial 1200.125: a Phase III randomized, open-label trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum based chemotherapy
Lung	Double blind randomized trial Phase III trial of Taxotere in the treatment of non small cell lung cancer in stage III-IV, Roger Bellon. Medical Department, Montpellier Regional Cancer Center; 1995
Lung	Protocol CLDK378A2301: A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer

---

Sarcoma	A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of AB1010 at 7,5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumor in first line medical treatment
---------	---

---

Supportive Care	Double blind randomized trial of DAU 6215, for the control of acute emesis in high dose cisplatin treated cancer patients, Boehringer Ingelheim France. Medical Department, Institute Gustave Roussy - Ville Juif; 1992 – 1994
Supportive Care	V212: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety, Efficacy and Tolerability of V212 in Adults with Solid Tumor or Hematologic Malignancy

## CLINICAL RESEARCH/Principal Investigator - Phase IV

FIELD	Title	Protocol	Outcome
Breast	Incidence of Her2-Neu status in newly diagnosed breast cancer: clinico-pathological correlation	Herbeat I	Article
Breast	Adhesion and Outcome of patients with Metastatic Breast Cancer (mBC) treated with Afinitor (Everolimus); A retrospective and prospective study in Lebanon	AfiMBC-OS 1317	Article
GI	A non-interventional multicenter study of first-line Eloxatin based chemotherapy in patients with metastatic colorectal cancer	AxELOx	
GI	A non-interventional multicenter study of first-line line Eloxatin based chemotherapy in patients with metastatic colo-rectal cancer	MACRO	
GI	An observation of the therapeutic management of patients receiving Erbitux (Cetuximab) for treatment of metastatic colorectal carcinoma	OBSERBI	
GI	A non-interventional multicenter study of first line Avastin® (bevacizumab) in combination with chemotherapy in patients with metastatic colorectal cancer	Llive	Article
GI	Incidence of HER2-neu status in newly diagnosed Gastric cancer patients: clinico-pathological correlation	Herbeat II	Article
Hematology	A Collaborative Nationwide Lymphoma Study in Lebanon: Incidence of Various Subtypes and Analysis of Associations with Viruses.	National Study	Article

**PROFESSIONAL INTERNATIONAL SOCIETIES MEMBERSHIPS**

- European Society of Medical Oncology (Certified member)
- European Association of Hematology
- American Society of Clinical Oncology
- Multinational Association of Supportive Care in Cancer
- International Association Study Lung Cancer
- French Society of Medical Pedagogy

**PROFESSIONAL NATIONAL INTERNATIONAL SOCIETIES MEMBERSHIPS**

- Lebanese Society of Medical Oncology
- Cancer Research Group-Collaborative Group
- Lebanese Society of Hematology and Blood Transfusion
- Lebanese Cancer Society

**GRANTS**

- Clinical Study for Gastrointestinal Stromal Tumors in Lebanon. Clinical Trial Protocol CSTI571BLB03T.Novartis
- AfME Registry on Gastro Intestinal Stromal Tumors : PProspective International/Intergroup Evaluation of Sunitinib Use. Pfizer

**INTERNATIONAL JOURNALS REVIEWER**

1. Cancer and Clinical Oncology
2. Cancer Chemotherapy and Pharmacology
3. Chemotherapy
4. Expert Review of Anticancer Therapy
5. Journal of Experimental & Clinical Cancer Research

6. Lebanese Medical Journal
7. PAJO
8. World Journal of Surgical Oncology (Senior/Scholar peer reviewer)

#### AWARDS

UPDATE LATER AND PUT ALL AWARDS, SCIENTIFIC AND SOCIAL

#### Consultancy & Advisory Boards

UPDATE LATER